Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sumul Raval

Neurology West Long Branch, NJ Medical Doctor

NPI 1376526673 CMS profile 61500

100 Hwy 36, Suite 1A, West Long Branch, NJ 07764

Open in the dashboard

General payments

$18,656

377 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$10,965 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Sumul Raval of West Long Branch, NJ is reported in the CMS Open Payments database as having received $18,656 across 377 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $10,965 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 82nd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,892 99
2024 General $1,644 110
2023 General $785 43
2022 General $2,507 11
2021 General $6,243 12
2020 General $4,563 29
2019 General $1,022 73

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sumul Raval
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Sumul Raval were reported at $1,892. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Sumul Raval Neurology median Middle half National median
2019 $1,022 $474 $118–$2,177 $163
2020 $4,563 $367 $82–$2,309 $114
2021 $6,243 $438 $104–$2,547 $132
2022 $2,507 $442 $103–$2,388 $149
2023 $785 $464 $119–$2,312 $160
2024 $1,644 $468 $119–$2,323 $164
2025 $1,892 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $8,466 30 payments
  2. Allergan Inc. $4,595 9 payments
  3. Pfizer Inc. $485 36 payments
  4. Novocure Inc. $382 18 payments
  5. Biogen, Inc. $341 23 payments
  6. ACADIA Pharmaceuticals Inc $330 32 payments
  7. Teva Pharmaceuticals USA, Inc. $299 14 payments
  8. Novartis Pharmaceuticals Corporation $294 16 payments
  9. Eisai Inc. $277 19 payments
  10. Boston Scientific Corporation $275 3 payments
  11. Other $2,912 177 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12,564 10 payments
  2. Food and Beverage $5,721 336 payments
  3. Education $372 31 payments
Products named General payments · program years 2019–2025
  1. UBRELVY Neuroscience $8,753 22 payments
  2. UBRELVY Neuroscience $4,195 8 payments
  3. NURTEC ODT $422 32 payments
  4. ZAVZPRET $347 26 payments
  5. NUPLAZID $291 29 payments
  6. QULIPTA $253 17 payments
  7. Leqembi $235 16 payments
  8. PURIFIED CORTROPHIN GEL $227 14 payments
  9. TYSABRI $225 13 payments
  10. Optune $178 8 payments
  11. Other $4,502 264 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 56 drugs

Part D claims

3,266

Median for Neurology: 833

Drug cost

$1,280,850

Median for Neurology: $202,670

Branded share of claims

30.5%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rebif Interferon Beta-1a/Albumin Brand 16 $231,446
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 25 $169,265
Vumerity Diroximel Fumarate Brand 16 $137,702
Kesimpta Pen Ofatumumab Brand 12 $104,888
Copaxone Glatiramer Acetate Brand 13 $74,599
Gammaked Immune Globul G/Gly/Iga Avg 46 Brand 12 $69,547
Briviact Brivaracetam Brand 36 $50,881
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 14 $50,003
Botox Onabotulinumtoxina Brand 35 $45,806
Vimpat Lacosamide Brand 22 $44,246

The 10 drugs with the highest cost, of 56 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$696,556

Medicare's payments for the services billed

Medicare patients

1,765

Average age 77

Services billed

8,245

970 women, 795 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 67%
Ischemic heart disease 54%
Diabetes 49%
Depression 43%
Chronic kidney disease 39%
Atrial fibrillation 36%
Heart failure 35%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 38 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUPLAZID
  • ACADIA Pharmaceuticals Inc $238
$238 — —
Leqembi
  • Eisai Inc. $158
$158 — —
NURTEC ODT
  • PFIZER INC. $112
$112 18 —
PURIFIED CORTROPHIN GEL
  • ANI Pharmaceuticals, Inc. $86
$86 — —
ZAVZPRET
  • PFIZER INC. $62
$62 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 38 with Patron

Records

377 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record